ClinicalTrials.gg
CompletedNCT06067828ATHLOSUpdated Mar 5, 2026

A Study to Evaluate the Effect of Budesonide, Glycopyrronium, Formoterol Fumarate (BGF) Metered Dose Inhaler (MDI), Budesonide and Formoterol Fumarate (BFF) MDI and Placebo MDI on Exercise Parameters in Participants With Chronic Obstructive Pulmonary Disease (COPD).

A Phase 3 interventional study of Treatment A : Budesonide, Glycopyrronium, and Formoterol Fumarate and Treatment B: Budesonide and Formoterol Fumarate in Chronic Obstructive Pulmonary Disease, sponsored by AstraZeneca. Completed at 33 sites in 7 countries. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-03-05.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
171
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies testing budesonide in Pulmonary Disease, Chronic Obstructive — 3 open to participants now, 3 under way, 1 of them phase 3. Budesonide · Pulmonary Disease, Chronic Obstructive.

Enrollment
16th of 43
171 · median 99
Started
2023
the only one that year
Phase 3
15 of 43
1 open now
Registered
39th of 43
by date
Lead sponsor
10 of 43
AstraZeneca

Among the 43 studies testing budesonide in Pulmonary Disease, Chronic Obstructive, this one is the 16th largest by enrollment, is the only one that started in 2023, is one of 15 in phase 3, and was the 39th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 857 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

3 of the 43 studies testing budesonide in Pulmonary Disease, Chronic Obstructive are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About budesonide

Budesonide: first FDA approval 1994 (RHINOCORT), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 557 Pulmonary Disease, Chronic Obstructive studies recruiting now, 306 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 89 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing budesonide in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

This study will investigate the effect of Budesonide, Glycopyrronium, and Formoterol Fumarate (BGF) metered dose inhaler (MDI) compared with Placebo MDI, and Budesonide and Formoterol Fumarate (BFF) MDI on isotime inspiratory capacity (IC) and exercise endurance time.

Read the detailed description

This is a multicenter, three-treatment, three-period, cross-over study to assess the effect of BGF MDI vs Placebo MDI and BFF MDI in participants with COPD who have exertional breathlessness despite treatment with mono or dual COPD maintenance therapy.

Eligible participants will be randomized equally (1:1:1:1:1:1) to 1 of 6 treatment sequences. The total duration of the study for each participant will be up to 14 weeks.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease

Keywords

  • Metered Dose Inhalers
04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be male or female, 40 to 80 years of age inclusive, at the time of signing the .
  • Participant must have:

    • a diagnosis of confirmed by a post-bronchodilator (FEV1)/ Forced vital capacity (FVC) \< 0.7 at Visit 1
    • a post-bronchodilator FEV1 ≥ 30% and \<80% predicted normal (moderate to severe COPD) at Visit 1.
    • a score of ≥ 2 on the modified Medical Research Council at Visit 1.
    • pre-bronchodilator FRC of > 120% of predicted normal FRC values at Visit 1.
    • a constant work rate test endurance time of 3 to 8 minutes at Visit 2.
  • Participant must be on a stable dose of mono-or dual inhaled maintenance COPD treatment for at least 6 weeks.
  • Current or former smoker with a history of ≥ 10 pack-years of tobacco smoking
  • \< 40 kg/m2.
  • Male and Female participants (not applicable for female participants with non-) and their partners must use an acceptable method of .

Exclusion criteria

Exclusion Criteria:

  • A current diagnosis of asthma, asthma- -overlap, or any other chronic respiratory disease other than COPD such as alpha-1 antitrypsin deficiency, active tuberculosis, lung cancer, lung fibrosis, sarcoidosis, interstitial lung disease and pulmonary hypertension.
  • Historical or current evidence of a disease
  • Participants on oxygen therapy or that desaturate significantly (\<82%) during exercise.
  • Participants who are enrolled or entering a pulmonary rehabilitation program during the study.
  • Participants who have cancer that has not been in complete remission for at least 5 years.
  • Participants with a diagnosis of narrow-angle glaucoma that has not been adequately treated and/or change in vision that may be relevant, in the opinion of the investigator.
  • Participants with symptomatic prostatic hypertrophy or bladder neck obstruction/urinary retention that, in the opinion of the investigator, is clinically significant.
  • Participants who have a history of to β2-agonists, budesonide or any other components, glycopyrronium or other muscarinic anticholinergics, or any component of the MDI or dry powder inhaler.
  • Participant with resting (5 minutes) oxygen saturation SaO2 in room air ≤ 85%.
  • A COPD exacerbation that requires hospitalization within 12 months prior to Visit 1 or a COPD exacerbation that requires systemic corticosteroids or antibiotics within 4 months of Visit 1.
  • Participants with to cardiopulmonary exercise testing (CPET).
  • Participants who have had a respiratory tract infection within 8 weeks prior to Visit 1 and/or during the screening period.
  • Participants with lung lobectomy, lung volume reduction or lung transplantation.
  • Unable to withhold short-acting bronchodilators for 6 hours prior to lung function testing at each study visit.
  • Known history of drug or alcohol abuse within 12 months.
  • Any regular recreational use of marijuana in the 12 months.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
171 participants (actual)

Study arms

  • Active comparator
    BGF MDI

    Pressurized MDI fixed combination product of Budesonide 160 μg, Glycopyrronium 7.2 μg, and Formoterol Fumarate 4.8 μg per actuation.

    Drug: Treatment A : Budesonide, Glycopyrronium, and Formoterol Fumarate

  • Active comparator
    BFF MDI

    Pressurized MDI fixed combination product of Budesonide 160 μg and Formoterol Fumarate 4.8 μg per actuation.

    Drug: Treatment B: Budesonide and Formoterol Fumarate

  • Placebo comparator
    Placebo

    Placebo as pressurized inhalation suspension.

    Drug: Treatment C : Placebo

Interventions

  • DrugTreatment A : Budesonide, Glycopyrronium, and Formoterol Fumarate

    Randomized participants will receive 2 inhalations of BGF MDI via oral inhalation twice daily (BID).

  • DrugTreatment B: Budesonide and Formoterol Fumarate

    Drug pages: Budesonide · Formoterol

    Randomized participants will receive 2 inhalations of BFF MDI via oral inhalation BID.

  • DrugTreatment C : Placebo

    Randomized participants will receive 2 inhalations of placebo MDI via oral inhalation BID.

06

What researchers measure

Primary outcomes

  1. Change from baseline in isotime Inspiratory capacity (IC)

    To assess the effect of BGF MDI relative to Placebo MDI and BGF MDI relative to BFF MDI on dynamic hyperinflation in participants with COPD.

    Time frame: 2 weeks post-treatment

Secondary outcomes

  1. Change from baseline in constant work rate cycle ergometry endurance time

    To assess the effect of BGF MDI relative to Placebo MDI, BGF MDI relative to BFF MDI and BFF MDI relative to Placebo MDI on exercise endurance time in participants with COPD.

    Time frame: 2 weeks post-treatment

  2. Change from baseline in Isotime dyspnea (NRS)

    To assess the effect of BGF MDI relative to Placebo MDI, BGF MDI relative to BFF MDI and BFF MDI relative to Placebo MDI on Isotime dyspnea in participants with COPD.

    Time frame: 2 weeks post-treatment

  3. Change from baseline in functional residual capacity (FRC)

    To assess the effect of BGF MDI relative to BFF MDI and BFF MDI relative to Placebo MDI on FRC in participants with COPD.

    Time frame: 2 weeks post-treatment

  4. Change from baseline in total lung capacity (TLC)

    To assess the effect of BGF MDI relative to BFF MDI and BFF MDI relative to Placebo MDI on TLC in participants with COPD.

    Time frame: 2 weeks post-treatment

  5. Change from baseline in residual volume (RV)

    To assess the effect of BGF MDI relative to BFF MDI and BFF MDI relative to Placebo MDI on RV in participants with COPD.

    Time frame: 2 weeks post-treatment

  6. Change from baseline in RV/TLC

    To assess the effect of BGF MDI relative to BFF MDI and BFF MDI relative to Placebo MDI on RV/TLC in participants with COPD.

    Time frame: 2 weeks post-treatment

  7. Change from baseline in specific airway conductance (sGaw)

    To assess the effect of BGF MDI relative to BFF MDI and BFF MDI relative to Placebo MDI on sGaw in participants with COPD.

    Time frame: 2 weeks post-treatment

  8. Change from baseline in static Inspiratory capacity (IC)

    To assess the effect of BGF MDI relative to BFF MDI and BFF MDI relative to Placebo MDI on static IC in participants with COPD.

    Time frame: 2 weeks post-treatment

  9. Number of participants with serious adverse events (SAEs) and adverse event leading to discontinuation of study intervention (DAEs).

    To assess the safety and tolerability of BGF MDI and BFF MDI.

    Time frame: 2 weeks post-treatment

07

Study locations

33 sites
  • Research Site
    Los Angeles, California 90095, United States
  • Research Site
    Tarzana, California 91356, United States
  • Research Site
    Torrance, California 90502, United States
  • Research Site
    Brooksville, Florida 34613, United States
  • Research Site
    Anderson, South Carolina 29621, United States
  • Research Site
    Greenville, South Carolina 29615, United States
  • Research Site
    Spartanburg, South Carolina 29303, United States
  • Research Site
    Edmonton, Alberta T6G 2B7, Canada
  • Research Site
    Kingston, Ontario K7L 2V7, Canada
  • Research Site
    Sainte-Foy, Quebec G1V 4G5, Canada
  • Research Site
    Guangzhou, 510163, China
  • Research Site
    Nanchang, 330006, China
  • Research Site
    Shenyang, 110001, China
  • Research Site
    Zhengzhou, 450000, China
  • Research Site
    Berlin, 12159, Germany
  • Research Site
    Berlin, 14050, Germany
  • Research Site
    Frankfurt, 60596, Germany
  • Research Site
    Großhansdorf, 22927, Germany
  • Research Site
    Hanover, 30449, Germany
  • Research Site
    Heidelberg, 69115, Germany
  • Research Site
    Lübeck, 23552, Germany
  • Research Site
    Mainz, 55128, Germany
  • Research Site
    Daegu, 42415, South Korea
  • Research Site
    Seoul, 02447, South Korea
  • Research Site
    Seoul, 05030, South Korea
  • Research Site
    Benalmádena, 29630, Spain
  • Research Site
    Madrid, 28007, Spain
  • Research Site
    Santiago de Compostela, 15706, Spain
  • Research Site
    Seville, 41013, Spain
  • Research Site
    Leicester, LE1 5WW, United Kingdom
  • Research Site
    London, SW3 6HP, United Kingdom
  • Research Site
    London, W1T 6AH, United Kingdom
  • Research Site
    Manchester, M23 9GP, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. "Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2023 to primary completion in Jan 2026, 26 months.

Of 108 industry-sponsored phase 3 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 36. This study's 26 months is above that.

Counting every sponsor, half of 141 studies reached it within 23 months; a quarter within 14 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2023
First posted
Oct 5, 2023
StartActual
Oct 24, 2023
Primary completionActual
Jan 22, 2026
CompletionActual
Jan 22, 2026
Last update
Mar 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06067828
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Oct 5, 2023
Start date
Oct 24, 2023
Primary completion
Jan 22, 2026
Completion
Jan 22, 2026
Last update
Mar 5, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Budesonide · Formoterol

Start the discussion